Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition

benzinga.com/m-a/25/09/47567454/novartis-to-expand-heart-drug-portfolio-with-1-4-billion-tourmaline-bio-acquisition

Tourmaline Bio, Inc. (NASDAQ:TRML) shares surged Tuesday after Novartis AG (NYSE:NVS) announced a $1.4 billion acquisition of the U.S.-based biotech, strengthening the Swiss drugmaker’s pipeline of cardiovascular and kidney treatments.
Novartis will pay $48.00 per share in cash at…

This story appeared on benzinga.com, 2025-09-09 12:10:32.
The Entire Business World on a Single Page. Free to Use →